Akt at the crossroads of microglial function: a double-edged sword in Alzheimer's disease neuroinflammation
International Immunopharmacology · 2026-07 · 181 · 116773
DOI: 10.1016/j.intimp.2026.116773 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-07. Verfasst von Yongxing Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Gannan Medical University, Ganzhou 341000, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Microglia, Neuroinflammatory Diseases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Ganzhou City Bureau of Science and Technology, Jiangxi Provincial Natural Science Foundation, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) pathology is increasingly understood to be driven by complex neuroinflammatory processes, with microglia-the resident immune cells of the brain playing a pivotal role. The PI3K/Akt signaling pathway serves as a critical intracellular hub, orchestrating the diverse and often opposing functions of microglia. This review synthesizes current insights into the multifaceted role of Akt signaling in modulating microglial activity in the context of AD. We explore the dualistic nature of Akt, which can promote pro-inflammatory neurotoxicity through pathways such as NF-κB while simultaneously mediating neuroprotective functions, including anti-inflammatory resolution, amyloid-β (Aβ) phagocytosis, and regulation of key clearance receptors like triggering receptor expressed on myeloid cells 2 (TREM2). Additionally, we examine how the Akt/mTOR axis governs microglial immunometabolism, facilitating the transition between glycolytic, pro-inflammatory states and oxidative phosphorylation-driven, phagocytic phenotypes. Emerging therapeutic strategies are discussed, including natural compounds, pharmacological agents, indirect modulation via the gut-brain axis and physical brain stimulation, as well as advanced nanotechnology platforms designed to target this pathway in microglia with precision. Finally, we address key challenges such as isoform specificity, therapeutic timing, and translational relevance, and outline future perspectives aimed at achieving "precision immunomodulation" of the Akt pathway. Such fine-tuning of microglial function represents a promising yet complex avenue for developing effective therapies to combat AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College of Gannan Medical University, Ganzhou 341000, China.
- The First Clinical Medical College of Gannan Medical University, Ganzhou 341000, China; Department of Anesthesiology, Ganzhou Key Laboratory of Anesthesiology, The First Affiliated Hospital of Gannan Medical University,…
Förderung
- Ganzhou City Bureau of Science and Technology
- Jiangxi Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Jiangxi Provincial Department of Education
Zitieren
APA
Xu, Y., Liang, W., Tang, Z., Lu, F., Xia, L., Xie, H., Zhong, M., & Li, S. (2026). Akt at the crossroads of microglial function: a double-edged sword in Alzheimer's disease neuroinflammation. International Immunopharmacology, 181, 116773. https://doi.org/10.1016/j.intimp.2026.116773
Vancouver
Xu Y, Liang W, Tang Z, Lu F, Xia L, Xie H, et al. Akt at the crossroads of microglial function: a double-edged sword in Alzheimer's disease neuroinflammation. International Immunopharmacology. 2026;181:116773. doi:10.1016/j.intimp.2026.116773
BibTeX
@article{Xu2026,
author = {Xu, Yongxing and Liang, Weidong and Tang, Zhikang and Lu, Feng and Xia, Lingyi and Xie, Haiyu and Zhong, Maolin and Li, Shihong},
title = {Akt at the crossroads of microglial function: a double-edged sword in Alzheimer's disease neuroinflammation},
journal = {International Immunopharmacology},
year = {2026},
volume = {181},
pages = {116773},
doi = {10.1016/j.intimp.2026.116773}
}
EUVIMED